BV6

Description	in vitro: BV6 treatment had no effect on necrotic cell death induced by poly(I:C)+IFNβ, anti-Fas+zVAD-fmk, or H2O2, but greatly sensitized cells to TNF-induced necrosis. As observed in L929 cells, BV6 treatment of FADD-deficient Jurkat cells led to a rapid loss of cIAP1 and cIAP2 and greatly sensitized these cells to TNF-induced necrosis . BV6 significantly enhances the radiosensitization of HCC193 and H460 cells in vitro . Four-hour pre-incubation with 2.5?μMol BV6 moderately enhanced CIK cell-mediated lysis of hematological (H9, THP-1, and Tanoue) and solid malignancies (RH1, RH30, and TE671). However, BV6 also increased apoptosis of non-malignant cells like peripheral blood mononuclear cells and most notably had an inhibitory effect on immune cells potentially limiting their cytotoxic potential .
Pathways	Apoptosis Pathway
Targets	IAP

Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.

For product details of different batches, please contact our Customer

Products are for research use only and not for human use. We do not sell to patients.